高级检索

SURGERY AND MULTIMODAL THERAPY IN COLON-ANG IN RECTAL CANCER

SURGERY AND MULTIMODAL THERAPY IN COLON-ANG IN RECTAL CANCER[J]. 实用临床医药杂志, 2005, (9): 9-27.
引用本文: SURGERY AND MULTIMODAL THERAPY IN COLON-ANG IN RECTAL CANCER[J]. 实用临床医药杂志, 2005, (9): 9-27.
shu

SURGERY AND MULTIMODAL THERAPY IN COLON-ANG IN RECTAL CANCER

  • 1.

    Surgical Center and Asklepios Tumortreatment Center Rhein-Main (ATC),Asklepios Paulinen Klinik (APK) Wiesbaden;

  • 2.

    Germany;

  • 3.

    Dept.General and Visceral Surgery,Puji Hospital,Yangzhou University, China

详细信息

  • 中图分类号: R6

摘要

    摘要
  • 摘要: 1 Summary The 5-year-survival rates of surgically treated patients are varying and depend on UICC stages/substages with remarkable variations in between published reports, surgical hospital units, individual surgeons, and continents. These variations may be due to surgical techniques, training status, hospital and individual case volume, but also on referral patterns, and statistical evaluation methods. Survival time and cure rates are significantly improved by modern adjuvant chemotherapy in colon cancers UICC Ⅲ and in substages of UICC Ⅱ (e.g. UICC Ⅱ B) by 5%-16%, and adjuvant radiochemotherapy in rectal cancer by 10%-14% when compared to surgical controls. In three modern colon cancer trials standard adjuvant chemotherapy was further improved by increasing the survival rates, e.g. from 59% to 71% in stage Ⅲ and IIB patients. In rectal cancer neoadjuvant radio(chemo)therapy decreases local relapse rates vs. postoperative adjuvant radio(chemo)therapy. Since surgery in rectal cancer has also been significantly improved by total mesorectal excision (TME) and better surgical training, the indications and methods for multimodal therapy have changed from UICC Ⅱ+Ⅲ to more individual criteria. Molecular and genetic factors, such as thymidylate synthase (TS), microsatellite instability (MSI) or loss of chromosome 18q/DCC might have an independent impact on prognosis in the spontaneous course, but could also help to individually select colon and rectal cancer patients and treatment protocols for multimodal therapy. Thus, surgery and multimodal therapy has become very complex, needs regularly be updated in competent reviews, and should be conducted in specialized centers of multi-and interdisciplinary excellence.
    • HTML全文
    • 参考文献(95)
  • Link K H, Staib L, Kreuser E D. Beger HG for the Forschungsgruppe Onkologie Gastrointestinaler Tumoren(FOGT).Adjuvant Treatment of Colon and Rectal Cancer:Impact of Chemotherapy, Radiotherapy, and Immunotherapy on Routine Postsurgical Patient Management [J]. RRCR, 1996.311.
    Staib L, Link K H, Blatz A, Beger H G. Surgery of Colorectal Cancer:Surgical Morbidity and Five-and Ten-year Results in 2004 Patients - Monoinstitutional Experience [J]. World Journal of Surgery, 2002, (26):59.
    Wittekind C, Meyer H J, Bootz F. UICC International Union Against Cancer TNM Klass fikation maligner Tumoren.6.Auflage [M]. Springer Verlag Berlin, Heidelberg, Tokio, New York, 2002.
    Compton C, Fenoglio-Preiser C M, Pettigrew N. 3.0.CO;2-T.aspx">American Joint Committee on Cancer Prognostic Factors Consensus Conference:Colorectal Working Group [J]. Cancer, 2000(7):1739.doi: 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T.
    Kaplan E, Meier P. Non-parametric estimation from incomplete observations [J]. Journal of the American Statistical Association, 1958.457.
    Link K H, Staib L, Bernhart H. Acceptance and Toxicity of Postoperative Adjuvant Therapy in Colon and Rectal Cancers.Interim Report on the Trials FOGT1 and FOGT2 of the German.Forschungsgruppe Onkologie Gastrointestinaler Tumoren(FOGT) [J]. Onkologie, 1997.235.doi: 10.1159/000218945.
    Staib L, Link K H, Beger H G. Toxicity and Effects of Adjuvant Therapy in Colon Cancer:Results of the German Prospective, Controlled Randomized Multicenter Trial FOGT-1 [J]. Journal of Gastrointestinal Surgery, 2001(5):275.doi: 10.1016/S1091-255X(01)80048-2.
    Kornmann M, Link K H, Staib L. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment:results of a randomized trial comparing modulation of 5-FU+levamisole with folinic acid or with interferon-alpha [J]. EJSO, 2004(2):127.
    Kornmann M, Schwabe W, Sander S. Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression Levels:Predictors for Survival in Colorectal Cancer Patients Receiving Adjuvant 5-Flurouracil [J]. Clinical Cancer Research, 2003.4116.
    Arbeitsgemeinschaft Bev. lkerungsbezogener Krebsregister in Deutschland in Zusammenarbeit mit dem Robert Koch Institut.Krebs in Deutschland Hufigkeiten und Trends [M]. Saarbrücken 3.Ausgabe, 2002.
    Taal B G, Van Tinteren H, Zoetmulder F A, NACCP group. Adjuvant 5-Fu plus levamisole in colonic or rectal cancer improvement in survival in stage Ⅱ and Ⅲ [J]. British Journal of Cancer, 2001, (10):1437.
    Link K H, Mrschel M, Sagban T A. Chirurgie und multimodale Therapie des Kolonkarzinoms:Evidenzbasis [J]. Chirurgische Gastroenterologie, 2004.39.
    Marsoni S. Fluorouracil and folinic acid in colon cancer.IMPACT Investigators [J]. LANCET, 1995, (8964):1582.
    H Brenner, V Arndt, T Stürmer. Long-lasting reduction of risk of colorectal cancer following screening endoscopy [J]. British Journal of Cancer, 2001(9):85, 972.
    Brenner H, Hakulinen T. On crude and age-adjusted relative survival rates [J]. Journal of Clinical Epidemiology, 2003, (12):1185.doi: 10.1016/S0895-4356(03)00209-9.
    Trojan J, Povse N, Stein J. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood [J]. Zeitschrift fur Gastroenterologie, 2002.921.
    Hermanek P, Mansmann U, Altendorf-Hofmann A. Vergleichende Beurteilung der onkologischen Ergebnisqualit?t beim colorectalen Carcinom.Klinikvergleiche anhand von Surogatendpunkten [J]. CHIRURG, 1999.407.
    Hermanek P, Wiebelt H, Staimmer D. Prognostic factors of rectum carcinoma-experience of the German Multicentre Study SGCRC [J]. German Study Group Colo-Rectal Carcinoma Tumori, 1995, (zk):60.
    Schrag D, Cramer L D, Bach P B. Influence of hospital procedure volume on outcomes following surgery for colon cancer [J]. Journal of the American Medical Association, 2000, (23):3028.doi: 10.1001/jama.284.23.3028.
    Wein A, Lehnert T, Liersch T. Quality controlled surgery in adjuvant treatment of colon cancer UICC Ⅲ:Intact-a multicenter phase III trial [J]. Journal of Cancer Research and Clinical Oncology, 2002(1):78.
    Smith M, Gurney J, Ries G L A. Cancer among adolescents 15-19 years old [A]. NIH Pub.No.99-4649.Bethseda, NIH, 1999.79.
    Ederer F, Geisser M S, Mongin S J. Colorectal cancer deaths as determined by expert committee and from death certificate:a comparison.Minnesota Study [J]. Journal of Clinical Epidemiology, 1999(5):447.
    Brenner H, Spix C. Combining cohort and period methods for retrospective time trend analyses of long-term cancer patient survival rates [J]. British Journal of Cancer, 2003.1260.
    McArdle C S, Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival [J]. British Medical Journal, 1991.1501.doi: 10.1136/bmj.302.6791.1501.
    Hermanek P, Wiebelt H. Langzeitergebnisse der chirurgischen Therapie des Kolonkarzinoms(Ergebnisse der Studiengruppe Kolorektales Karzinom) [J]. Chirurg, 1994.287.
    Martling A L, Holm T, Rutqvist L E. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project [J]. LANCET, 2000, (9224):93.doi: 10.1016/S0140-6736(00)02469-7.
    MacFarlane J K, Ryall R D, Heald R J. Mesorectal excision for rectal cancer [J]. Lancet, 1993, (8843):457.
    Matzel KE, Stadelmaier U, Hohenfellner M, Hohenberger W. Chronic sacral spinal nerve stimulation for fecal incontinence:long-term results with foramen and cuff electrodes [J]. Diseases of the Colon & Rectum, 2001(1):59.
    Nesbakken A, Nygaard K, Lunde O C. Mesorectal excision for rectal cancer:functional outcome after low anterior resection and colorectal anastomosis without a reservoir [J]. Colorectal Disease, 2002(3):172.doi: 10.1046/j.1463-1318.2002.00305.x.
    Gill S, Loprinzi C L, Sargent D J. Pooled analysis of fluorouracil-based adjuvant therapy for stage Ⅱ and Ⅲ colon cancer:who benefits and by how much [J]. Journal of Clinical Oncology, 2004, (10):1797.
    Meyerhardt J A, Catalano P J, Schrag D. Association of Hospital Procedure Volume and Outcomes in Patients with Colon Cancer at High Risk for Recurrence [J]. Annals of Internal Medicine, 2003.649.
    Birkmeyer J D, Siewers A E, Finlayson E. Hospital Volume and Surgical Mortality in the United States [J]. New England Journal of Medicine, 2002.1128.
    Martling A, Cedermark B, Johansson H. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer [J]. British Journal of Surgery, 2002(8):1008.
    Bulow S, Christensen I J, Harling H. RANX05 Colorectal Cancer Study Group.Recurrence and survival after mesorectal excision for rectal cancer [J]. British Journal of Surgery, 2003(8):974.
    Stocchi L, Nelson H, Sargent D J. Impact of surgical and pathologic variables in rectal cancer:a United States community and cooperative group report [J]. Journal of Clinical Oncology, 2001, (18):3895.
    Willett C G, Badizadegan K, Ancukiewicz M. Prognostic factors in stag T3N0 rectal cancer:do all patients require postoperative pelvic irradiation and chemotherapy [J]. Diseases of the Colon & Rectum, 1999(2):167.
    Nagtegaal I D, van de Velde C J, van der Worp E. Macroscopic evaluation of rectal cancer resection specimen:clinical significance of the pathologist in quality control [J]. Journal of Clinical Oncology, 2002(7):1729.
    Wibe A, Rendedal P R, Svensson E. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer [J]. British Journal of Surgery, 2002(3):327.
    Birbeck K F, Macklin C P, Tiffin N J. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery [J]. ANNALS OF SURGERY, 2002(4):449.
    Adam I J, Mohamdee M O, Martin I G. Role of circumferential margin involvement in the local recurrence of rectal cancer [J]. LANCET, 1994, (8924):707.doi: 10.1016/S0140-6736(94)92206-3.
    Quirke P, Durdey P, Dixon M F. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection.Histopathological study of lateral tumour spread and surgical excision [J]. Lancet, 1986, (8514):996.
    Hermanek P, Mansmann U, Altendorf-Hofmann A. Comparative study of oncological outcome quality in colorectal carcinoma-ranking by surrogate endpoint [J]. CHIRURG, 1999(4):407.doi: 10.1007/s001040050664.
    Heald R J, Karanjia N D. Results of radical surgery for rectal cancer [J]. World Journal of Surgery, 1992(5):848.doi: 10.1007/BF02066981.
    Mori T, Takahashi K, Yasuno M. Radical resection with autonomic nerve preservation and lymph node dissection techniques in lower rectal cancer surgery and its results:the impact of lateral lymph node dissection [J]. Langenbecks Archives of Surgery, 1998(6):409.
    Link K H, Sagban T A, Appell. Chirurgie und multimodale Therapie des Kolonkarzinoms:Evidenzbasis [J]. Chirurgische Gastroenterologie, 2004.39.
    Martling A, Cedermark B, Johansson H. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer [J]. British Journal of Surgery, 2002(8):1008.
    Martling A L, Holm T, Rutqvist L E. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm.Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project [J]. LANCET, 2000, (9224):93.doi: 10.1016/S0140-6736(00)02469-7.
    Herrera-Ornelas L, Justiniano J, Castillo N. Metastases in small lymph nodes from colon cancer [J]. Archives of Surgery, 1987, (11):1253.
    Joseph N E, Sigurdson E R, Hanlon A L. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection [J]. Annals of Surgical Oncology, 2003(3):213.
    Le Voyer T E, Sigurdson E R, Hanlon A L. Colon cancer survival is associated with increasing number of lymph nodes analyzed:a secondary survey of intergroup trial INT-0089 [J]. Journal of Clinical Oncology, 2003, (15):2912.
    Tepper J E. Adjuvant radiation therapy of rectal cancer [J]. Journal of Clinical Oncology, 2001, (17):3709.
    Kockerling F, Reymond M A, Altendorf-Hofmann A. Influence of surgery on metachronous distant metastases and survival in rectal cancer [J]. Journal of Clinical Oncology, 1998(1):324.
    Francini G, Petrioloi R, Lorenzini L. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer [J]. GASTROENTEROLOGY, 1994(4):899.
    Fingerhut A, Msika S, Yahchouchi E. Neither pelvic nor abdominal drainage is needed after anastomosis in elective, uncomplicated, colorectal surgery [J]. Annals of Surgery, 2000(4):613.doi: 10.1097/00000658-200004000-00023.
    The Axis collaborators. Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer(AXIS) [J]. British Journal of Surgery, 2003, (10):1200.doi: 10.1002/bjs.4266.
    Gatta G, Capocaccia R, Coleman M P. Toward a comparison of survival in American and European cancer patients [J]. Cancer, 2000(4):893.
    Moertel C G, Fleming T R, Macdonald J S. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma [J]. New England Journal of Medicine, 1990.
    Shirao K, Hoff P M, Ohtsu A. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur(UFT) plus oral leucovorin(LV) regimen between Japanese and American patients with advanced colorectal cancer:joint United States and Japan study of UFT/LV [J]. Journal of Clinical Oncology, 2004, (17):3466.doi: 10.1200/JCO.2004.05.017.
    Scheithauer W, McKendrick J, Begbie S. Oral capecetabine as an alternative to i.v.5-Fluorouracil-based djuvant therapy for colon cancer:safety results of a randomized, phase Ⅲ trial [J]. Annals of Oncology, 2003, (12):1735.doi: 10.1093/annonc/mdg500.
    De Gramont A, Banzi M, Navarro M. Oxaliplatin/5-Fu/LV in adjuvant colon cancer:Results of the international randomized mosaic trial [M]. ASCO, 2003.
    Saini A, Norman A R, Cunningham D. Twelve weeks of protracted venous infusion of fluorouracil(5-Fu) is as effective as 6 months of bolus 5-Fu and folinic acid as adjuvant treatment in colorectal cancer [J]. British Journal of Cancer, 2003, (12):1859.doi: 10.1038/sj.bjc.6600995.
    Andre T, Colin P, Louvet C. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage Ⅱ and Ⅲ colon cancer:results of a randomized trial [J]. Journal of Clinical Oncology, 2003, (15):2896.
    Kim D J, Kim T I, Suh J H. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer [J]. Yonsei Medical Journal, 2003(4):665.
    Seitz J F. 5-fluorouracil/leucovorin versus capecitabine in patients with stage Ⅲ colon cancer [J]. Seminars in Oncology, 2001, (z1):41.
    Scheithauer W, McKendrick J, Begbie S. Oral capecitabine as an alternative to i.v.5-fluorouracil-based adjuvant therapy for colon cancer:safety results of a randomized, phase Ⅲ trial [J]. Annals of Oncology, 2003, (12):1735.
    Sakamoto J, Ohashi Y, Hamada C. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum; Meta-Analysis Group in Cancer.Efficacy of oral adjuvant therapy after resection of colorectal cancer:5-year results from three randomized trials [J]. Journal of Clinical Oncology, 2004(3):484.
    Wolmark N, Rockette H, Fisher B. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant chemotherapy for primary colon cancer:results from National Surgical Adjuvant Breast and Bowl Project protocol C-01 [J]. Journal of Clinical Oncology, 1993, (10):1879.
    Haller D G, Catalano P J, MacDonald J S. Fluorouracil(Fu), leucovorin(LV), and levamisole(LEV) adjuvant therapy for colon cancer:Five year final report of ITN-0089 [J]. Proceedings of ASCO, 1998.256a.
    O′Connell M J, Martenson J A, Wieand H S. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery [J]. New England Journal of Medicine, 1994(8):502.
    Porschen R, Bermann A, Loffler T. Arbeitsgemeinschaft Gastrointestinale Onkologie Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage Ⅲ colon cancer:results of the trial adjCCA-01 [J]. Journal of Clinical Oncology, 2001(6):1787.
    Martenson JA Jr, Willett C G, Sargent D J. Phase Ⅲ study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer:results of intergroup protocol 0130 [J]. Journal of Clinical Oncology, 2004, (16):3277.doi: 10.1200/JCO.2004.01.029.
    Figueredo A, Charette M L, Maroun J. Adjuvant therapy for stage Ⅱ colon cancer:a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group [J]. Journal of Clinical Oncology, 2004, (16):3395.
    Link K H, Staib L, Kornmann M. Forschungsgruppe Onkologie Gastrointestinale Tumoren.Surgery, radio-and chemotherapy for multimodal treatment of rectal cancer [J]. Swiss Surgery, 2001(6):256.doi: 10.1024/1023-9332.7.6.256.
    Ooi B S, Tjandra J J, Green M D. Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer:an overview [J]. Diseases of the Colon & Rectum, 1999(3):403.
    Roh M S, Petrelli N, Wieand S. Phase Ⅲ randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum(NSABP R-03 [J]. Proceedings of ASCO, 2001.490.
    Kapiteijn E, Marijnen C A, Nagtegaal I D. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer [J]. New England Journal of Medicine, 2001(9):638.doi: 10.1056/NEJMoa010580.
    Wolmark N, Wieand H S, Hyams D M. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum:National Surgical Adjuvant Breast and Bowel Project Protocol R-02 [J]. Journal of the National Cancer Institute, 2000(5):388.
    Bagatzounis A, Willner J, Oppitz U. The postoperative adjuvant radiation therapy and radiochemotherapy for UICC stage Ⅱ and Ⅲ rectal cancer.A retrospective analysis [J]. Strahlentherapie Und Onkologie, 2000(3):112.doi: 10.1007/PL00002335.
    Tepper J E, O′Connell M J, Petroni G R. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer:initial results of intergroup 0114 [J]. Journal of Clinical Oncology, 1997(5):2030.
    Staib L. Adjuvant radiochemotherapy in resectable stage Ⅱ, Ⅲ rectal cancer:Results of the FOGT-2 trial [J]. Proceedings of ASCO, 2004.3608.
    Safi F, Link K H, Beger H G. Is follow-up of colorectal cancer patients worthwhile [J]. Diseases of the Colon & Rectum, 1993(7):636.
    Staib L, Link K H, Beger HG. Tumornachsorge bei Kolon-/Rektumkarzinom heute-Kosten-/Nutzeneffekt der nachsorge [M]. Postgraduiertenkurs Kolon-/Rektumkarzinom-116.Kongress der Deutschen Gesellschaft für Chirurgie, 1999.
    Schorr M, Siebeck M, Zoller W G. Patientenorientierte, risikoadaptierte Tumornachsorge bei Patienten mit kolorectalem Karzinom [J]. Zeitschrift fur Gastroenterologie, 1997.1019.
    Graupe F, Schwenk F, Bracht B. Die psychische Belastung von Patienten in der Tumornachsorge nach R0-Resektion colorectaler Carcinome [J]. CHIRURG, 1996.604.
    Odin E, Wettergren Y, Nilsson S. Altered Gene Expression of Folate Enzymes in Adjacent Mucosa Is Associated with Outcome of Colorectal Cancer Patients [J]. Clinical Cancer Research, 2003.6012.
    Edler D, Glimelius B, Hallstrom M. Thymidylate synthase expression in colorectal cancer:a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy [J]. Journal of Clinical Oncology, 2002(7):1721.
    Watanabe T, Wu T T, Catalano P J. Molecular predictors of survival after adjuvant chemotherapy for colon cancer [J]. New England Journal of Medicine, 2001, (16):1196.doi: 10.1056/NEJM200104193441603.
    Elsaleh H, Powell B, McCaul K. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage Ⅲ colorectal carcinoma [J]. Clin Cancer Res, 2001(5):1343.
    Link K H, Aigner K R, Peschau K. Concentration and time dependence of the toxicity of fluorinated pyrimidines to HAT 29 colorectal carcinoma cells [J]. Cancer Chemotherapy and Pharmacology, 1988(1):58.
    Kornmann M, Link K H, Lenz H J. Thymidilate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy [J]. Cancer Letters, 1997.29.doi: 10.1016/S0304-3835(97)00220-6.
    Link K H, Sunelaitis E, Kornmann M. 3.0.CO;2-Q.aspx">Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival [J]. Cancer, 2001, (11):2746.doi: 10.1002/1097-0142(20011201)92:11<2746::AID-CNCR10098>3.0.CO;2-Q.
    Siewert J R, Huber F T, Sendler A. Abdominal recurrence after interventions on the intestines [J]. CHIRURG, 1995, (10):941.
    Lacy A M, Garcia-Valdecasas J C, Delgado S. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer:a randomised trial [J]. LANCET, 2002, (9325):2224.
    Miller L, Emanuel D, Elfring G. 60-day, all-cause mortality with first-line irinotecan/fluorouracil/leucovorin(IFL) or fluorouracil/leucovorin(FL) for metastatic colorectal cancer(MCRC) [J]. Proceedings of ASCO, 2002.515.
    Louvet C, Andre T, Tigaud J M. Phase Ⅱ study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients [J]. Journal of Clinical Oncology, 2002, (23):4543.doi: 10.1200/JCO.2002.02.021.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量: 
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 发布日期:  2005-11-30

目录

摘要
HTML全文
    参考文献(95)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    x 关闭 永久关闭